Rivaroxaban-induced liver injury: Results from a venous thromboembolism registry

International Journal of Cardiology

Volumn 191, Issue , 2015, Pages 265-266

  Lambert, Aude ^a   Cordeanu, Mihaela ^b   Gaertner, Sébastien ^b   Nouri, Salah ^b   Alt, Martine ^a   Stephan, Dominique ^a,b  

^a Regional Pharmacovigilance Centre   (France)

^b Strasbourg Regional University Hospital   (France)

Author keywords

Drug induced liver injury; Rivaroxaban; Venous thromboembolism

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ESOMEPRAZOLE; LIVER ENZYME; PARACETAMOL; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHOLESTASIS; CLINICAL ARTICLE; DISEASE REGISTRY; DRUG RECHALLENGE; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; HOSPITAL DISCHARGE; HUMAN; LIVER CELL DAMAGE; LIVER FUNCTION; LIVER INJURY; LIVER TOXICITY; LUNG EMBOLISM; MALE; NAUSEA; PATHOPHYSIOLOGY; PATIENT MONITORING; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM; VOMITING; DRUG-INDUCED LIVER INJURY; MIDDLE AGED; PROSPECTIVE STUDY; REGISTER;

ADULT; AGED; DRUG-INDUCED LIVER INJURY; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; RIVAROXABAN; VENOUS THROMBOEMBOLISM;

EID: 84938204026     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.04.248     Document Type: Article

References (11)

1. M. Keisu, and T.B. Andersson Drug-induced liver injury in humans: the case of ximelagatran Handb. Exp. Pharmacol. 2010 407 418
2. P.B. Watkins, M. Desai, S.D. Berkowitz, G. Peters, Y. Horsmans, D. Larrey, and W. Maddrey Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery Drug Saf. 34 3 2011 243 252
3. D. Caldeira, M. Barra, A.T. Santos, and et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis Heart 100 2014 550 556
4. S. Russmann, D.F. Niedrig, M. Budmiger, and et al. Rivaroxaban postmarketing risk of liver injury J. Hepatol. 61 2014 293 300
5. E. Liakoni, A.E. Rätz Bravo, L. Terracciano, M. Heim, and S. Krähenbühl Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban JAMA Intern. Med. 174 2014 1683 1686
6. Observational Prospectif Monocentric Registry of patients suffering from VTE - REMOTEV NCT02188056 2014
7. G. Danan, and C. Benichou Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries J. Clin. Epidemiol. 46 1993 1323 1330
8. Eudravigilance Xarelto January 2015
9. A. Raschi, E. Poluzzi, A. Koci, and et al. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration Adverse Event Reporting System Br. J. Clin. Pharmacol. 2015 10.1111/bcp.12611
10. ANSM Réunion du Comité technique de Pharmacovigilance - CT012013083 November 2013 (http://ansm.sante.fr/)
11. S. Aslan, M. Meral, M. Akgun, and et al. Liver dysfunction in patients with acute pulmonary embolism Hepatol. Res. 37 2007 205 213